Qpex Biopharma and Brii Biosciences Enter Into a Strategic Collaboration to Develop and Commercialize Antibiotics for Drug-Resistant Infections in China
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
SAN DIEGO,?Oct. 22, 2019?/PRNewswire/ -- Qpex Biopharma, Inc., a biopharmaceutical company dedicated to the discovery and development of innovative anti-infective therapies, today announced that it has entered into a multi-product collaboration with Brii Biosciences to develop and commercialize Qpex's portfolio in?China?of potentially best-in-class therapies to treat a range of multi-drug resistant gram-negative infections.
"We are thrilled to be working together with a team that shares our vision and dedication to address the global antimicrobial resistance problem," said?Michael Dudley, Pharm.D., President and CEO of Qpex Biopharma. "Brii Bio's depth of understanding in this field and their unique, cross-regional operating model make them the ideal collaborator in bringing our treatments to this important region where endemic drug-resistance problems can be well addressed by our portfolio."
The portfolio includes the following investigational products:
- OMNIvance: an intravenous-administered, beta-lactamase inhibitor (BLI) based product that may provide best-in-class coverage of?Acinetobacter?species,?Enterobacteriaceae, and Pseudomonas aeruginosa, including carbapenem-resistant strains
- ORAvance: an orally-administered BLI combination for the treatment of multi-drug resistant gram-negative infections in outpatient settings, or to allow hospitalized patients to switch from IV to oral therapy
- Next-generation polymyxin: an IV-administered, targeted spectrum synthetic polymyxin with an enhanced therapeutic profile designed to address highly resistant infections caused by?Pseudomonas?and?Acinetobacter